Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure

American Journal of Cardiology

Volumn 112, Issue 6, 2013, Pages 831-837

  Lok, Dirk J ^a   Klip, Ijsbrand T ^b   Lok, Sjoukje I ^c   De La Porte, Pieta W Bruggink André ^a   Badings, Erik ^a   Van Wijngaarden, Jan ^a   Voors, Adriaan A ^b   De Boer, Rudolf A ^b   Van Veldhuisen, Dirk J ^b   Van Der Meer, Peter ^a,b  

^a DEVENTER HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; TROPONIN T;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PROGNOSIS; BLOOD; DISEASE COURSE; METABOLISM; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; HEART FAILURE; HUMANS; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TROPONIN T;

EID: 84886698796     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.05.013     Document Type: Article

References (29)

1. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GYH, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-869.
2. van Veldhuisen DJ, Linssen GCM, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JPG, Paulus WJ, Voors AA, Hillege HL. Brain natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013;61:1498-1506.
3. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357-2368.
4. Bruins S, Fokkema MR, Römer JWP, Dejongste MJL, van der Dijs FPL, van den Ouweland JMW, Muskiet FAJ. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052-2058.
5. Kempf T, Haehling von S, Peter T, Allhoff T, Cicoira M, Doehner W, Ponikowski P, Filippatos GS, Rozentryt P, Drexler H, Anker SD, Wollert KC. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007;50: 1054-1060.
6. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H, Wollert KC. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010;122:1387-1395.
7. Niizeki T, Takeishi Y, Kitahara T, Suzuki S, Sasaki T, Ishino M, Kubota I. Combination of conventional biomarkers for risk stratification in chronic heart failure. J Cardiol 2009;53:179-187.
8. Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AHB, Goldberg LR, Jessup M, Cappola TP. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 2012;5:183-190.
9. Lok DJA, Van Der Meer P, la Porte de PWB-A, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99: 323-328.
10. de Boer RA, Lok DJA, Jaarsma T, Van Der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43:60-68.
11. Masson S, Anand I, Favero C, Barlera S, Vago T, Bertocchi F, Maggioni AP, Tavazzi L, Tognoni G, Cohn JN, Latini R. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from two large randomized clinical trials. Circulation 2012;125:280-288.
12. Egstrup M, Schou M, Tuxen CD, Kistorp CN, Hildebrandt PR, Gustafsson F, Faber J, Goetze J-P, Gustafsson I. Prediction of outcome by highly sensitive troponin T in outpatients with chronic systolic left ventricular heart failure. Am J Cardiol 2012;110:552-557.
13. Bruggink-André de la Porte PWF, Lok DJA, Van Wijngaarden J, Cornel JH, Pruijsers-Lamers D, van Veldhuisen DJ, Hoes AW. Heart failure programmes in countries with a primary care-based health care system. Are additional trials necessary? Design of the DEAL-HF study. Eur J Heart Fail 2005;7:910-920.
14. la Porte de PWFB-A, Lok DJA, van Veldhuisen DJ, Van Wijngaarden J, Cornel JH, Zuithoff NPA, Badings E, Hoes AW. Added value of a physician-and-nurse- directed heart failure clinic: results from the Deventer-Alkmaar heart failure study. Heart 2007;93:819-825.
15. Remme W. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-1560.
16. Smilde TDJ, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006;114:1572-1580.
17. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845.
18. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172; discussion 207-12.
19. Tulevski II, Hirsch A, Sanson BJ, Romkes H, van der Wall EE, van Veldhuisen DJ, Büller HR, Mulder BJ. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost 2001;86:1193-1196.
20. Andreadis EA, Georgiopoulos DX, Tzavara CK, Katsanou PM, Fragouli EG, Mavrokefalou EM, Chatzis NA, Ifanti GK, Diamantopoulos EJ. Plasma brain natriuretic peptide: a biochemical marker of effective blood pressure management? J Hypertens 2009;27:425-432.
21. Giannessi D. Multimarker approach for heart failure management: perspectives and limitations. Pharmacol Res 2011;64:11-24.
22. Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M,Korf-Klingebiel M,NappLC,Hansen B,Kanwischer A, Bavendiek U, Beutel G, Hapke M, Sauer MG, Laudanna C, Hogg N, Vestweber D, Wollert KC. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011;17:581-588.
23. Lok SI, Winkens B, Goldschmeding R, van Geffen AJP, Nous FMA, van Kuik J, van der Weide P, Klöpping C, Kirkels JH, Lahpor JR, Doevendans PA, de Jonge N, de Weger RA. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail 2012 Nov;14: 1249-1256.
24. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L. Prognostic value of growthdifferentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007;115:962-971.
25. Kempf T, Björklund E, Olofsson S, Lindahl B, Allhoff T, Peter T, Tongers J, Wollert KC, Wallentin L. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J 2007;28:2858-2865.
26. Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, Ho JE, Fradley MG, Ghorbani A, Xanthakis V, Kempf T, Benjamin EJ, Levy D, Vasan RS, Januzzi JL. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012;126:1596-1604.
27. Tang WHW, Shrestha K, Van Lente F, Troughton RW, Martin MG, Borowski AG, Jasper S, Klein AL. Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. Am J Cardiol 2008;101:370-373.
28. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009;11:811-817.
29. Kawahara C, Tsutamoto T, Sakai H, Nishiyama K, Yamaji M, Fujii M, Yamamoto T, Horie M. Prognostic value of serial measurements of highly sensitive cardiac troponin I in stable outpatients with nonischemic chronic heart failure. Am Heart J 2011;162:639-645.